Evidence map›Paper›PMID 30800666›Full record

ArticleBioMed research international2019

Evidence for Clonally Associated Increasing Rates of Azithromycin Resistant

Késia T Barros Dos Santos, Larissa B Skaf, Livia H Justo-da-Silva, Raphael C Medeiros, Ronaldo da S Francisco Junior, Maria Cristina A Caniné, Sergio E L Fracalanzza, Raquel R Bonelli

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Global status of Azithromycin and Erythromycin Resistance Rates inThe Yale journal of biology and medicine · 2022
    Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Késia T Barros Dos SantosInstituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Larissa B SkafInstituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Livia H Justo-da-SilvaInstituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Raphael C MedeirosInstituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Ronaldo da S Francisco JuniorLaboratório Nacional de Computação Científica, Petrópolis, 26651-075, Brazil.
Maria Cristina A CaninéDASA-Rua Xavier Pinheiro, 439, Parque Duque, 25085-007, Duque de Caxias, RJ, Brazil.
Sergio E L FracalanzzaInstituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Raquel R BonelliInstituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0003-4537-5458
Universidade Federal do Rio de Janeiro · BRLaboratório Nacional de Computação Científica · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azithromycin is one of the drugs used in the combined therapy for syndromic treatment of gonorrhoea in many countries, including Brazil. Our research group, which receives isolates from clinical laboratories since 2006, has detected, after 2016, a tendency of rising rates of azithromycin resistance, with isolates showing higher minimal inhibitory concentrations (MICs) than those previously reported in this country. In this study, we report the susceptibility to azithromycin of 93

Indexed as

AdolescentAdultAgedAnti-Bacterial AgentsAzithromycinBrazilCeftriaxoneCiprofloxacinDrug Resistance, BacterialFemaleGonorrheaHumansMaleMicrobial Sensitivity TestsMiddle AgedMutationAnti-Bacterial AgentsAzithromycinCeftriaxoneCiprofloxacin

Identifiers

PMID30800666
PMCPMC6360546
OpenAlexW2909418474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.